2. Academic Validation
  3. Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors

Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors

  • J Med Chem. 2018 May 24;61(10):4386-4396. doi: 10.1021/acs.jmedchem.8b00060.
Jacek Kwiatkowski 1,  Boping Liu 1,  Doris Hui Ying Tee 1,  Guoying Chen 1,  Nur Huda Binte Ahmad 1,  Yun Xuan Wong 1,  Zhi Ying Poh 1,  Shi Hua Ang 1,  Eldwin Sum Wai Tan 1,  Esther Hq Ong 1,  Nurul Dinie 1,  Anders Poulsen 1,  Vishal Pendharkar 1,  Kanda Sangthongpitag 1,  May Ann Lee 1,  Sugunavathi Sepramaniam 1,  Soo Yei Ho 1,  Joseph Cherian 1,  Jeffrey Hill 1,  Thomas H Keller 1,  Alvin W Hung 1
Affiliations

Affiliation

  • 1 Experimental Therapeutics Centre , Agency for Science, Technology and Research (A*STAR) , 11 Biopolis Way, Helios #03-10/11 , Singapore 138667 , Singapore.
PMID: 29688013 DOI: 10.1021/acs.jmedchem.8b00060
Abstract

Protein kinase C iota (PKC-ι) is an atypical kinase implicated in the promotion of different Cancer types. A biochemical screen of a fragment library has identified several hits from which an azaindole-based scaffold was chosen for optimization. Driven by a structure-activity relationship and supported by molecular modeling, a weakly bound fragment was systematically grown into a potent and selective inhibitor against PKC-ι.

Figures
Products